Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma

NCT03463460 is registered in ClinicalTrials.gov with Dwight Owen as lead sponsor.

NCT NCT03463460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03463460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma
Lead sponsor
Dwight Owen
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 19, 2018
Completion date
April 30, 2027
Enrollment
9 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

thymic carcinoma